BioXcel Therapeutics, Inc. (BTAI) Q3 2023 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, and welcome to the BioXcel Therapeutics Conference Call, which will cover its alignment with the FDA on its Tranquility Program, provide an update on strategic financing, and review its financial results for the third quarter of 2023. At this time, all participants are in a listen-only mode. If during the conference you require operator assistance, please press star zero on your telephone keypad. After the presentation, there will be a question and answer session. If you would like to register a question, you may press star 1 on your telephone keypad. Just to remind everyone, certain matters discussed in today's conference call and or answers that may be given to questions asked are forward-looking statements that are subject to risks and uncertainties related to future events and or the future financial or business performance of the company. Actual results could differ materially from those anticipated in these forward-looking statements. Risk factors that may affect future results are detailed in the company's quarterly report on Form 10-Q for the quarter ended June 30, 2023, which can be found at www.bioexceltherapeutics.com or on www.sec.gov, and which will be updated in its quarterly report on Form 10-Q for the quarter ended September 30, 2023. As a reminder, today's conference is being recorded. Presenting on today's call are Dr. Vimal Mehta, Chief Executive Officer, and Richard Steinhardt, Chief Financial Officer. Joining them for participation in the Q&A session are Matt Wiley, Chief Commercial Officer, Dr. Rob Reisinger, Chief Medical Officer of Neuroscience, Dr. Vince O'Neill, Chief R&D Officer of Oncosexcel Therapeutics, and Dr. Frank Yaka, Chief Scientific Officer. It is now my pleasure to turn the call over to Dr. Mehta. Thank you, Operato...